© June 2026 | IJIRT | Volume 13 Issue 1 | ISSN: 2349-6002

Analytical Approaches for the Simultaneous Determination of Bronchodilator and Corticosteroid Drugs in Pharmaceutical Formulations: A Review

Sushant B. Yedage[1], Dr Samrat Khedkar[2]
[1,2]*Vidyaniketan College of Pharmacy Lakevadi, Ahilyanagar Sangola, Solapur, Maharashtra, India*

Abstract—**Respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD) are commonly treated using combinations of bronchodilator and corticosteroid drugs. Accurate and reliable analytical methods are essential for the quality control, stability assessment, and regulatory compliance of these pharmaceutical formulations. Reverse-phase high-performance liquid chromatography (RP-HPLC) has emerged as one of the most widely used analytical techniques for the simultaneous estimation of respiratory drug combinations due to its high sensitivity, selectivity, precision, and reproducibility. This review summarizes the current approaches employed in RP-HPLC method development and validation for bronchodilator and corticosteroid combinations in bulk drugs and pharmaceutical dosage forms. Key aspects such as chromatographic optimization, mobile phase selection, method validation parameters, and regulatory requirements are discussed. In addition, recent advancements including Quality by Design (QbD), Design of Experiments (DoE), and analytical lifecycle management are highlighted. The review emphasizes the importance of robust analytical methods in ensuring pharmaceutical product quality, safety, and therapeutic efficacy.**

Index Terms—**RP-HPLC, Bronchodilator, Corticosteroid, Method Validation, Pharmaceutical Analysis.**

I. INTRODUCTION

Respiratory diseases are among the most common chronic health disorders affecting millions of people worldwide. Asthma and Chronic Obstructive Pulmonary Disease (COPD) are major respiratory conditions characterized by airway inflammation, airflow obstruction, and breathing difficulties. These diseases significantly affect the quality of life of patients and contribute to substantial healthcare costs globally. According to the Global Initiative for Asthma (GINA) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD), the prevalence of respiratory disorders continues to increase due to environmental pollution, smoking, occupational exposure, and genetic factors. Bronchodilators and corticosteroids are the most commonly prescribed medications for the management of respiratory disorders. Bronchodilators act by relaxing the smooth muscles of the airways, thereby improving airflow and reducing symptoms such as wheezing, coughing, and shortness of breath. They are classified into β2-adrenergic agonists, anticholinergics, and methylxanthines based on their mechanism of action. These drugs provide rapid and effective relief from bronchoconstriction and are considered essential components of asthma and COPD therapy.

Corticosteroids play a vital role in controlling airway inflammation associated with respiratory diseases. These agents reduce inflammatory mediator release, suppress immune responses, and decrease airway hyperresponsiveness. Inhaled corticosteroids are commonly used as maintenance therapy because they effectively prevent exacerbations and improve lung function while minimizing systemic side effects. The combination of corticosteroids with bronchodilators has become a standard treatment approach for achieving optimal therapeutic outcomes in patients with chronic respiratory disorders.

Combination therapy involving bronchodilators and corticosteroids has gained considerable importance due to its enhanced therapeutic effectiveness compared to monotherapy. The simultaneous administration of these agents provides both rapid symptom relief and long-term control of airway inflammation. This synergistic approach improves patient compliance, reduces disease exacerbations, and enhances overall treatment efficacy. Consequently, combination pharmaceutical formulations containing bronchodilators and corticosteroids have become widely available in the form of inhalers, nebulizer solutions, and other dosage forms.

The increasing use of combination drug products has created a need for reliable analytical methods capable of simultaneously determining multiple active pharmaceutical ingredients in pharmaceutical formulations. Analytical methods play a critical role in drug development, formulation optimization, quality control, stability assessment, and regulatory compliance. Accurate analytical procedures ensure that pharmaceutical products meet predefined quality standards and contain the correct amount of active ingredients throughout their shelf life.

Various analytical techniques have been employed for the determination of pharmaceutical compounds, including spectrophotometry, thin-layer chromatography (TLC), high-performance thin-layer chromatography (HPTLC), gas chromatography (GC), and high-performance liquid chromatography (HPLC). Among these methods, chromatographic techniques are widely preferred because of their superior sensitivity, selectivity, accuracy, and reproducibility. Chromatography enables efficient separation of active pharmaceutical ingredients from impurities, degradation products, and formulation excipients.

Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) has emerged as one of the most important analytical tools in pharmaceutical analysis. RP-HPLC utilizes a non-polar stationary phase and a polar mobile phase to achieve efficient separation of compounds based on their hydrophobic interactions. This technique offers several advantages, including high resolution, excellent reproducibility, short analysis time, and compatibility with a wide range of pharmaceutical compounds. RP-HPLC is therefore extensively employed for routine quality control, assay determination, dissolution testing, impurity profiling, and stability studies. Method development is a crucial step in establishing a reliable RP-HPLC procedure. The development process involves selecting appropriate chromatographic conditions such as stationary phase, mobile phase composition, buffer pH, flow rate, column temperature, and detection wavelength. Optimization of these parameters is necessary to achieve satisfactory separation, acceptable peak shape, suitable retention time, and high analytical sensitivity. Traditionally, analytical methods were developed using a trial-and-error approach; however, modern pharmaceutical industries increasingly adopt systematic and scientific approaches for method development.

In recent years, the Quality by Design (QbD) concept has transformed analytical method development. QbD is a science-based and risk-oriented approach that emphasizes method understanding and process control. The approach begins with defining an Analytical Target Profile (ATP), followed by identification of Critical Quality Attributes (CQAs) and Critical Method Parameters (CMPs). Risk assessment tools such as Ishikawa diagrams and Failure Mode and Effects Analysis (FMEA) are commonly used to identify variables that may affect analytical performance. This approach improves method robustness and regulatory acceptance. Design of Experiments (DoE) has become an important component of analytical Quality by Design. DoE allows simultaneous evaluation of multiple variables and their interactions using statistical techniques. Experimental designs such as factorial design, Box-Behnken design, and central composite design are frequently used to optimize chromatographic conditions. The application of DoE reduces experimental effort, improves method understanding, and facilitates the establishment of a design space for consistent analytical performance. After optimization, analytical methods must undergo validation to demonstrate their suitability for the intended purpose. Regulatory agencies recommend validation according to International Council for Harmonisation (ICH) guidelines. Validation parameters typically include specificity, linearity, accuracy, precision, robustness, limit of detection (LOD), limit of quantification (LOQ), and system suitability. Proper validation ensures reliability, reproducibility, and regulatory compliance of the developed method.

Recent advancements in pharmaceutical analysis have further improved the capabilities of RP-HPLC. The integration of ultra-performance liquid chromatography (UPLC), mass spectrometric detection, automated data processing systems, and analytical lifecycle management has enhanced

analytical efficiency and sensitivity. Moreover, the adoption of green analytical chemistry principles aims to reduce solvent consumption and environmental impact while maintaining analytical performance.
Therefore, the present review focuses on analytical approaches employed for the simultaneous determination of bronchodilator and corticosteroid drugs in pharmaceutical formulations, with particular emphasis on RP-HPLC method development, optimization strategies, validation requirements, and recent advancements in pharmaceutical analysis.

II. RP-HPLC METHOD DEVELOPMENT

RP-HPLC (Reverse Phase High-Performance Liquid Chromatography) is one of the most widely used analytical techniques in pharmaceutical analysis because of its high sensitivity, accuracy, precision, and reproducibility. Method development is a systematic process aimed at establishing suitable chromatographic conditions for the effective separation and quantification of pharmaceutical compounds. The primary objective is to obtain acceptable retention time, resolution, peak symmetry, and reproducibility while minimizing analysis time and solvent consumption. During method development, several factors such as column selection, mobile phase composition, buffer pH, flow rate, column temperature, and detection wavelength are optimized to achieve desired analytical performance. A properly developed RP-HPLC method ensures reliable analysis of active pharmaceutical ingredients, impurities, degradation products, and excipients present in pharmaceutical formulations.

Table 1. Important Parameters in RP-HPLC Method Development

Parameter	Purpose
Column Selection	Provides efficient separation and peak resolution
Mobile Phase Composition	Controls retention and selectivity
Buffer pH	Influences ionization and peak shape
Flow Rate	Affects retention time and efficiency
Column Temperature	Improves reproducibility and peak symmetry
Detection Wavelength	Provides maximum analyte sensitivity
Injection Volume	Ensures consistent peak response

III. RP-HPLC METHOD OPTIMIZATION STRATEGIES

Method optimization involves systematic adjustment of chromatographic variables to achieve the best analytical performance. Traditionally, optimization was performed using a one-factor-at-a-time (OFAT) approach, where a single parameter was changed while others remained constant. However, this method is time-consuming and may overlook interactions between variables. Modern pharmaceutical analysis employs Quality by Design (QbD) and Design of Experiments (DoE) approaches to optimize chromatographic conditions efficiently. DoE allows simultaneous evaluation of multiple variables and their interactions, leading to better method understanding and robustness. Optimization aims to achieve acceptable retention time, high resolution, low tailing factor, and adequate theoretical plate count.

Table 2. Common Variables Optimized During RP-HPLC Method Development

Variable	Effect on Chromatographic Performance
Organic Solvent Ratio	Influences retention time and resolution
Buffer Concentration	Affects peak shape and reproducibility
Mobile Phase pH	Controls analyte ionization
Flow Rate	Alters analysis time and efficiency
Column Temperature	Improves peak symmetry and resolution
Detection Wavelength	Enhances sensitivity and selectivity

Table 3. Common Experimental Designs Used in DoE

Design Type	Application
Full Factorial Design	Screening of critical variables
Fractional Factorial Design	Evaluation of multiple factors with fewer experiments
Box-Behnken Design	Optimization of chromatographic conditions
Central Composite Design (CCD)	Response surface modeling and optimization
Plackett-Burman Design	Preliminary screening studies

IV. VALIDATION REQUIREMENTS OF RP-HPLC METHODS

Method validation is performed to demonstrate that an analytical method is suitable for its intended purpose. According to ICH Q2(R2) guidelines, validation ensures reliability, reproducibility, and accuracy of analytical results. Validation parameters are evaluated using predefined acceptance criteria and documented according to regulatory requirements. Validation is essential before implementing a method for routine quality control analysis.

Table 4. Validation Parameters According to ICH Guidelines

Parameter	Purpose
Specificity	Ability to measure analyte in presence of impurities and excipients
Linearity	Demonstrates proportionality between concentration and response
Accuracy	Closeness of measured value to true value
Precision	Reproducibility of analytical results
Repeatability	Precision under same operating conditions
Intermediate Precision	Precision under different analysts or days
Range	Concentration interval showing acceptable performance
LOD	Lowest detectable analyte concentration
LOQ	Lowest quantifiable analyte concentration
Robustness	Ability to remain unaffected by small changes
System Suitability	Verifies chromatographic system performance

Table 5. Typical Acceptance Criteria for Validation

Parameter	Acceptance Criteria
Linearity	Correlation coefficient (R^2) ≥ 0.999
Accuracy	Recovery 98–102%
Precision	%RSD ≤ 2%
Robustness	No significant effect on results
Tailing Factor	≤ 2.0
Theoretical Plates	≥ 2000

V. RECENT ADVANCEMENTS IN PHARMACEUTICAL ANALYSIS

Pharmaceutical analysis has evolved significantly due to advancements in instrumentation, automation, and regulatory expectations. Modern analytical technologies have improved method sensitivity, selectivity, speed, and robustness. The integration of advanced chromatographic techniques, risk-based approaches, and data analytics has transformed pharmaceutical quality control and research. These innovations facilitate rapid method development, improved regulatory compliance, and enhanced product quality.

Table 6. Recent Advancements in Pharmaceutical Analysis

Advancement	Significance
Ultra-Performance Liquid Chromatography (UPLC)	Faster analysis and higher resolution
LC-MS/MS	Highly sensitive drug and impurity analysis
High-Resolution Mass Spectrometry (HRMS)	Accurate mass measurement and structural characterization
Quality by Design (QbD)	Systematic and risk-based method development
Design of Experiments (DoE)	Efficient optimization of analytical methods
Process Analytical Technology (PAT)	Real-time process monitoring
Artificial Intelligence (AI)	Data interpretation and predictive modeling
Machine Learning	Optimization and automated decision-making
Green Analytical Chemistry	Reduction of solvent consumption and waste
Analytical Lifecycle Management (ALM)	Continuous monitoring and improvement of methods

Table 7. Benefits of Modern Analytical Approaches

Approach	Major Benefits
QbD	Improved robustness and regulatory flexibility
DoE	Reduced experimentation and better optimization
UPLC	Shorter run time and higher efficiency
LC-MS/MS	Enhanced sensitivity and selectivity
AI-Based Analysis	Faster data processing and prediction
Green Chemistry	Sustainable and eco-friendly analysis

VI. CONCLUSION

Reverse Phase High-Performance Liquid Chromatography (RP-HPLC) remains one of the most reliable and widely used analytical techniques for the simultaneous determination of bronchodilator and corticosteroid drugs in pharmaceutical formulations.

The technique offers excellent sensitivity, accuracy, precision, selectivity, and reproducibility, making it suitable for routine quality control and stability studies. Proper method development and optimization are essential to achieve efficient separation, acceptable retention time, and robust analytical performance. Modern approaches such as Quality by Design (QbD) and Design of Experiments (DoE) have significantly improved method understanding, optimization, and robustness while reducing development time and experimental effort. Furthermore, validation of analytical methods according to ICH guidelines ensures the reliability and suitability of the developed procedure for its intended purpose. Recent advancements, including UPLC, LC-MS/MS, artificial intelligence, and green analytical chemistry, have further enhanced pharmaceutical analysis. Overall, RP-HPLC continues to play a crucial role in ensuring the quality, safety, efficacy, and regulatory compliance of combination respiratory drug products.

REFERENCES

[1] Global Initiative for Asthma (GINA), Global Strategy for Asthma Management and Prevention, 2024.

[2] Global Initiative for Chronic Obstructive Lung Disease (GOLD), Global Strategy for Diagnosis, Management and Prevention of COPD, 2024.

[3] H. P. Rang, J. M. Ritter, R. J. Flower, and G. Henderson, Rang and Dale's Pharmacology, 10th ed. Amsterdam, Netherlands: Elsevier, 2023.

[4] B. G. Katzung, Basic and Clinical Pharmacology, 16th ed. New York, NY, USA: McGraw-Hill Education, 2024.

[5] L. S. Goodman and A. Gilman, The Pharmacological Basis of Therapeutics, 14th ed. New York, NY, USA: McGraw-Hill, 2023.

[6] L. R. Snyder, J. J. Kirkland, and J. W. Dolan, Introduction to Modern Liquid Chromatography, 3rd ed. Hoboken, NJ, USA: John Wiley & Sons, 2019.

[7] M. W. Dong, Modern HPLC for Practicing Scientists, 2nd ed. Hoboken, NJ, USA: John Wiley & Sons, 2019.

[8] Y. Kazakevich and R. LoBrutto, HPLC for Pharmaceutical Scientists. Hoboken, NJ, USA: John Wiley & Sons, 2007.

[9] S. Ahuja and M. W. Dong, Handbook of Pharmaceutical Analysis by HPLC, 2nd ed. Burlington, MA, USA: Elsevier Academic Press, 2011.

[10] G. L. Reid, J. Morgado, K. Barnett, B. Harrington, J. Wang, and J. W. Harwood, “Analytical Quality by Design (AQbD),” Pharmaceutical Technology, vol. 37, no. 6, pp. 52–59, 2013.

[11] D. C. Montgomery, Design and Analysis of Experiments, 10th ed. Hoboken, NJ, USA: John Wiley & Sons, 2020.

[12] International Council for Harmonisation (ICH), ICH Q2(R2): Validation of Analytical Procedures. Geneva, Switzerland: ICH, 2023.

[13] E. Rozet, E. Ziemons, R. D. Marini, B. Boulanger, and P. Hubert, “Quality by Design compliant analytical method validation,” Journal of Pharmaceutical and Biomedical Analysis, vol. 55, no. 4, pp. 848–858, 2013.

[14] L. R. Snyder, J. J. Kirkland, and J. W. Dolan, Introduction to Modern Liquid Chromatography, 3rd ed. Hoboken, NJ, USA: John Wiley & Sons, 2019.

[15] Y. Kazakevich and R. LoBrutto, HPLC for Pharmaceutical Scientists. Hoboken, NJ, USA: John Wiley & Sons, 2007.

[16] S. Ahuja and M. W. Dong, Handbook of Pharmaceutical Analysis by HPLC, 2nd ed. Amsterdam, Netherlands: Elsevier, 2011.

[17] D. C. Montgomery, Design and Analysis of Experiments, 10th ed. Hoboken, NJ, USA: Wiley, 2020.

[18] International Council for Harmonisation (ICH), ICH Q2(R2): Validation of Analytical Procedures. Geneva, Switzerland, 2023.

[19] G. L. Reid, J. Morgado, K. Barnett, et al., “Analytical Quality by Design (AQbD),” Pharmaceutical Technology, vol. 37, no. 6, pp. 52–59, 2013.

[20] E. Rozet, E. Ziemons, R. D. Marini, B. Boulanger, and P. Hubert, “Quality by Design compliant analytical method validation,” J. Pharm. Biomed. Anal., vol. 55, no. 4, pp. 848–858, 2013.